Business combination consideration liability settled.

No definition available.

Name:	dna_BusinessCombinationConsiderationLiabilitySettled
Namespace Prefix:	dna_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Debt Instrument Unpaid Principal Amount

+ References

No definition available.

+ Details

Name:	dna_DebtInstrumentUnpaidPrincipalAmount
Namespace Prefix:	dna_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Decrease in the fair value of the contingent consideration liability.

+ References

No definition available.

+ Details

Name:	dna_DecreaseInTheFairValueOfTheContingentConsiderationLiability
Namespace Prefix:	dna_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payment for achievement of a technical development milestone

+ References

No definition available.

+ Details

Name:	dna_PaymentForAchievementOfATechnicalDevelopmentMilestone
Namespace Prefix:	dna_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Probabilities rate

+ References

No definition available.

+ Details

Name:	dna_ProbabilitiesRate
Namespace Prefix:	dna_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Recovery rate on first lien debt

+ References

No definition available.

+ Details

Name:	dna_RecoveryRateOnFirstLienDebt
Namespace Prefix:	dna_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Share based compensation arrangement by share based payment award fair value assumptions risk adjsuted Interest rate

+ References

No definition available.

+ Details

Name:	dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskAdjsutedInterestRate
Namespace Prefix:	dna_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Years to maturity

+ References

No definition available.

+ Details

Name:	dna_YearsToMaturity
Namespace Prefix:	dna_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228

+ Details

Name:	us-gaap_AssetImpairmentCharges
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of warrants or rights outstanding.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69C
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1D
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611

+ Details

Name:	us-gaap_DebtInstrumentFairValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentInterestRateEffectivePercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Rate of weighted-average expected volatility for award under share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_InvestmentTypeAxis=dna_GenomaticaIncPreferredStocksMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=dna_FgenAgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=dna_DutchDnaBiotechBvMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=dna_PromissoryNoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=dna_GlycosynPromissoryNoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=dna_PublicWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=dna_PrivatePlacementWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dna_AccessBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Jul. 01, 2021
Volatility			72.20%		85.50%
Years to Maturity			4 months 17 days		10 months 17 days
Risk Free Interest Rate			3.25%		0.30%
Risk adjusted rate			33.9
Expected Dividend Yield			0.00%		0.00%
Genomatica Inc Preferred Stock [Member]
Impairment charges	$ 10,100,000	$ 0		$ 0
FGen AG [Member]
Contingent consideration, included in other non-current liabilities	25,000,000.0		$ 25,000,000.0
Business combination consideration liability settled	1,900,000
Dutch Dna Biotech BV [Member]
Contingent consideration, included in other non-current liabilities						$ 20,000,000.0
Decrease in the fair value of the contingent consideration liability	$ 700,000		700,000
Payment for achievement of a technical development milestone			$ 700,000
Promissory Note [Member]
Probabilities rate			50.00%		50.00%
Recovery rate on first lien debt	63.00%		63.00%		63.00%
Discount Rate	15.00%		15.00%		15.00%
Glycosyn Promissory Note [Member]
Unpaid Principal Amount	$ 5,400,000		$ 5,400,000		$ 5,400,000
Fair Value Of Promissory Note	$ 1,800		$ 1,800		1,800
Level 3 \| Public Warrants [Member]
Assumed Class Of Warrant Or Right Outstanding	34,499,925		34,499,925
Level 3 \| Private Placement Warrants [Member]
Assumed Class Of Warrant Or Right Outstanding	17,325,000		17,325,000
Access Bio [Member]
Unpaid Principal Amount	$ 10,000,000.0		$ 10,000,000.0		10,000,000.0
Fair Value Of Promissory Note	$ 9,500,000		$ 9,500,000		$ 9,800,000
Risk Free Interest Rate			2.10%
Risk adjusted rate					30.9